Assessment and treatment of suicide risk in schizophrenia

References

• Miles CP. Conditions predisposing to suicide: a review. J. Nerv. Ment. Dis.164(4), 231–246 (1977).
   PubMed Web of Science ®Google Scholar
• Caldwell CB, Gottesman II. Schizophrenia – a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat. Behav.22(4), 479–493 (1992).
   PubMed Web of Science ®Google Scholar
• Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry172, 35–37 (1998).
   PubMed Web of Science ®Google Scholar
• Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry62(3), 247–253 (2005).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Suicidality in schizophrenia: pharmacologic treatment. Clin. Neuropsychiatry2(1), 76–83 (2005).
   Google Scholar
• Lester D. Sex differences in completed suicide by schizophrenic patients: a meta-analysis. Suicide Life Threat. Behav.36(1), 50–56 (2006).
   PubMed Web of Science ®Google Scholar
• Kraepelin E. Dementia Praecox and Paraphrenia. Livingstone, Edinburgh, UK (1919).
   Google Scholar
• Bleuler E. Dementia Praecox or the Group Schizophrenias. International University Press, NY, USA (1950).
   Google Scholar
• Lipschutz LS. Some administrative aspects of suicides in the mental hospital. Am. J. Psychiatry99, 181–187 (1942).
   Google Scholar
• Beisser AR, Blanchette JE. A study of suicides in a mental hospital. Dis. Nerv. Syst.22, 365–369 (1961).
   PubMedGoogle Scholar
• Pompili M, Amador XF, Girardi P et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann. Gen. Psychiatry6, 10 (2007).
   PubMedGoogle Scholar
• Tatarelli R, Pompili M, Girardi P. Suicide in Schizophrenia. Nova Science Publishers, Inc., NY, USA (2007).
   Google Scholar
• Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess? Arch. Gen. Psychiatry35(10), 1181–1185 (1978).
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting a shortened survival. Arch. Gen. Psychiatry37(9), 979–983 (1980).
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry64(10), 1123–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry177, 212–217 (2000).
   PubMed Web of Science ®Google Scholar
• Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf.15(12), 873–879 (2006).
   PubMed Web of Science ®Google Scholar
• Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J. Clin. Psychiatry68(Suppl. 4), 4–7 (2007).
   PubMed Web of Science ®Google Scholar
• Drake RE, Gates C, Cotton PG, Whitaker A. Suicide among schizophrenics. Who is at risk? J. Nerv. Ment. Dis.172(10), 613–617 (1984).
   PubMed Web of Science ®Google Scholar
• Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatr. Scand.74(1), 43–49 (1986).
   PubMed Web of Science ®Google Scholar
• Steblaj A, Tavcar R, Dernovsek MZ. Predictors of suicide in psychiatric hospital. Acta Psychiatr. Scand.100(5), 383–388 (1999).
   PubMed Web of Science ®Google Scholar
• Heila H, Isometsa ET, Henriksson MM et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am. J. Psychiatry154(9), 1235–1242 (1997).
   PubMed Web of Science ®Google Scholar
• Nyman AK, Jonsson H. Patterns of self-destructive behaviour in schizophrenia. Acta Psychiatr. Scand.73(3), 252–262 (1986).
   PubMed Web of Science ®Google Scholar
• Barak Y, Knobler CY, Aizenberg D. Suicide attempts amongst elderly schizophrenia patients: a 10-year case–control study. Schizophr. Res.71(1), 77–81 (2004).
   PubMedGoogle Scholar
• Heila H, Haukka J, Suvisaari J, Lonnqvist J. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol. Med.35(5), 725–732 (2005).
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br. J. Psychiatry163, 183–189 (1993).
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res.45(1–2), 21–28 (2000).
   PubMed Web of Science ®Google Scholar
• Phillips MR, Yang G, Li S, Li Y. Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. Lancet364(9439), 1062–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt IM, Kapur N, Windfuhr K et al. Suicide in schizophrenia: findings from a national clinical survey. J. Psychiatr. Pract.12(3), 139–147 (2006).
   PubMedGoogle Scholar
• Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am. J. Psychiatry154(2), 199–204 (1997).
   PubMed Web of Science ®Google Scholar
• Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. Suicide Life Threat. Behav.30(1), 34–49 (2000).
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Tsai SY, Lo CH, Wang YP, Chen CC. Risk factors for completed suicide in schizophrenia. J. Clin. Psychiatry66(5), 579–585 (2005).
   PubMed Web of Science ®Google Scholar
• Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry187, 9–20 (2005).
   PubMed Web of Science ®Google Scholar
• De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr. Res.47(2–3), 127–134 (2001).
   PubMed Web of Science ®Google Scholar
• Westermeyer JF, Harrow M, Marengo JT. Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J. Nerv. Ment. Dis.179(5), 259–266 (1991).
   PubMed Web of Science ®Google Scholar
• Hu WH, Sun CM, Lee CT et al. A clinical study of schizophrenic suicides. 42 cases in Taiwan. Schizophr. Res.5(1), 43–50 (1991).
   PubMed Web of Science ®Google Scholar
• Krupinski M, Fischer A, Grohmann R et al. [Schizophrenic psychoses and suicide in the clinic. Risk factors, psychopharmacologic treatment]. Nervenarzt71(11), 906–911 (2000).
   PubMed Web of Science ®Google Scholar
• Saarinen PI, Lehtonen J, Lonnqvist J. Suicide risk in schizophrenia: an analysis of 17 consecutive suicides. Schizophr. Bull.25(3), 533–542 (1999).
   PubMed Web of Science ®Google Scholar
• Roy A. Suicide in chronic schizophrenia. Br. J. Psychiatry141, 171–177 (1982).
   PubMed Web of Science ®Google Scholar
• Zisook S, Byrd D, Kuck J, Jeste DV. Command hallucinations in outpatients with schizophrenia. J. Clin. Psychiatry56(10), 462–465 (1995).
   PubMed Web of Science ®Google Scholar
• Kelly DL, Shim JC, Feldman SM, Yu Y, Conley RR. Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. J. Psychiatr. Res.38(5), 531–536 (2004).
   PubMedGoogle Scholar
• Kreyenbuhl JA, Kelly DL, Conley RR. Circumstances of suicide among individuals with schizophrenia. Schizophr. Res.58(2–3), 253–261 (2002).
   PubMed Web of Science ®Google Scholar
• Heila H, Isometsa ET, Henriksson MM et al. Antecedents of suicide in people with schizophrenia. Br. J. Psychiatry173, 330–333 (1998).
   PubMedGoogle Scholar
• Funahashi T, Ibuki Y, Domon Y et al. A clinical study on suicide among schizophrenics. Psychiatry Clin. Neurosci.54(2), 173–179 (2000).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP. Assessment of suicidality in schizophrenia. In: Intervention Strategies for Suicidality. Meltzer HY, Conley RR, De Leo D et al. (Eds). J. Clin. Psychiatry Audiograph6, 1–16 (2003).
   Google Scholar
• Cheng KK, Leung CM, Lo WH, Lam TH. Risk factors of suicide among schizophrenics. Acta Psychiatr. Scand.81(3), 220–224 (1990).
   PubMed Web of Science ®Google Scholar
• Breier A, Astrachan BM. Characterization of schizophrenic patients who commit suicide. Am. J. Psychiatry141(2), 206–209 (1984).
   PubMed Web of Science ®Google Scholar
• Shields LB, Hunsaker DM, Hunsaker JC III. Schizophrenia and suicide: a 10-year review of Kentucky medical examiner cases. J. Forensic Sci.52(4), 930–937 (2007).
   PubMedGoogle Scholar
• Pompili M, Mancinelli I, Ruberto A et al. Where schizophrenic patients commit suicide: a review of suicide among inpatients and former inpatients. Int. J. Psychiatry Med.35(2), 171–190 (2005).
   PubMed Web of Science ®Google Scholar
• Nordentoft M, Mortensen PB. Hospital admission and suicide in schizophrenia. In: Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Science Publishers, NY, USA 61–76 (2007).
   Google Scholar
• Goldacre M, Seagroatt V, Hawton K. Suicide after discharge from psychiatric inpatient care. Lancet342(8866), 283–286 (1993).
   PubMed Web of Science ®Google Scholar
• Appleby L, Shaw J, Amos T et al. Suicide within 12 months of contact with mental health services: national clinical survey. Br. Med. J.318(7193), 1235–1239 (1999).
   PubMed Web of Science ®Google Scholar
• Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case–control study. Br. J. Psychiatry171, 355–359 (1997).
   PubMed Web of Science ®Google Scholar
• Lawrence DM, Holman CD, Jablensky AV, Fuller SA. Suicide rates in psychiatric in-patients: an application of record linkage to mental health research. Aust. NZ J. Public Health23(5), 468–470 (1999).
   PubMedGoogle Scholar
• Sinclair JM, Mullee MA, King EA, Baldwin DS. Suicide in schizophrenia: a retrospective case–control study of 51 suicides. Schizophr. Bull.30(4), 803–811 (2004).
   PubMed Web of Science ®Google Scholar
• Karvonen K, Sammela HL, Rahikkala H et al. Sex, timing, and depression among suicide victims with schizophrenia. Compr. Psychiatry48(4), 319–322 (2007).
   PubMed Web of Science ®Google Scholar
• Kan CK, Ho TP, Dong JY, Dunn EL. Risk factors for suicide in the immediate post-discharge period. Soc. Psychiatry Psychiatr. Epidemiol.42(3), 208–214 (2007).
   PubMed Web of Science ®Google Scholar
• Nordentoft M, Jeppesen P, Abel M et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. Br. J. Psychiatry Suppl.43, S98–S106 (2002).
   Google Scholar
• Melle I, Johannesen JO, Friis S et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am. J. Psychiatry163(5), 800–804 (2006).
   PubMed Web of Science ®Google Scholar
• Harkavy-Friedman JM. Can early detection of psychosis prevent suicidal behavior? Am. J. Psychiatry163(5), 768–770 (2006).
   PubMedGoogle Scholar
• Power PJ, Bell RJ, Mills R et al. Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Aust. NZ J. Psychiatry37(4), 414–420 (2003).
   PubMed Web of Science ®Google Scholar
• Pompili M, Ruberto A, Kotzalidis GD, Girardi P, Tatarelli R. Suicide and awareness of illness in schizophrenia: an overview. Bull. Menninger Clin.68(4), 297–318 (2004).
   PubMed Web of Science ®Google Scholar
• Crumlish N, Whitty P, Kamali M et al. Early insight predicts depression and attempted suicide after 4 years in first-episode schizophrenia and schizophreniform disorder. Acta Psychiatr. Scand.112(6), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Krausz M, Muller-Thomsen T, Haasen C. Suicide among schizophrenic adolescents in the long-term course of illness. Psychopathology28(2), 95–103 (1995).
   PubMed Web of Science ®Google Scholar
• Thorup A, Petersen L, Jeppesen P et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J. Nerv. Ment. Dis.195(5), 396–405 (2007).
   PubMed Web of Science ®Google Scholar
• Radomsky ED, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiatry156(10), 1590–1595 (1999).
   PubMed Web of Science ®Google Scholar
• Planansky K, Johnston R. The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr. Scand.47(4), 473–483 (1971).
   PubMed Web of Science ®Google Scholar
• Harkavy-Friedman JM, Restifo K, Malaspina D et al. Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide. Am. J. Psychiatry156(8), 1276–1278 (1999).
   PubMed Web of Science ®Google Scholar
• Roy A, Mazonson A, Pickar D. Attempted suicide in chronic schizophrenia. Br. J. Psychiatry144, 303–306 (1984).
   PubMed Web of Science ®Google Scholar
• Gupta S, Black DW, Arndt S, Hubbard WC, Andreasen NC. Factors associated with suicide attempts among patients with schizophrenia. Psychiatr. Serv.49(10), 1353–1355 (1998).
   PubMed Web of Science ®Google Scholar
• Drake RE. Suicide attempts and completed suicides among achizophrenia patients. In: Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Science Publishers, NY, USA 77–81 (2007).
   Google Scholar
• Drake RE, Gates C, Cotton PG. Suicide among schizophrenics: a comparison of attempters and completed suicides. Br. J. Psychiatry149, 784–787 (1986).
   PubMed Web of Science ®Google Scholar
• Hansen L, Jones RM, Kingdon D. No association between akathisia or parkinsonism and suicidality in treatment-resistant schizophrenia. J. Psychopharmacol.18(3), 384–387 (2004).
   PubMed Web of Science ®Google Scholar
• Muller DJ, Barkow K, Kovalenko S et al. Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics. Eur. Psychiatry20(1), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Sevincok L, Akoglu A, Kokcu F. Suicidality in schizophrenic patients with and without obsessive–compulsive disorder. Schizophr. Res.90(1–3), 198–202 (2007).
   PubMed Web of Science ®Google Scholar
• Sakinofsky I, Heila H, Krishnan R. Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. Schizophr. Bull.30(3), 587–598 (2004).
   PubMedGoogle Scholar
• Taiminen T, Huttunen J, Heila H et al. The Schizophrenia Suicide Risk Scale (SSRS): development and initial validation. Schizophr. Res.47(2–3), 199–213 (2001).
   PubMed Web of Science ®Google Scholar
• Turner RM, Korslund KE, Barnett BE, Josiassen RC. Assessment of suicide in schizophrenia: development of the Interview for Suicide in Schizophrenia. Cogn. Behav. Pract.5(2), 139–169 (1998).
   Google Scholar
• Korslund KE. Psychometric evaluation of the Interview for Suicide in Schizophrenia-Third Revision. Dissertation Abstracts International: Section B: The Sciences and Engineering.62(2-B) (2001).
   Google Scholar
• Lindenmayer JP, Czobor P, Alphs L et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr. Res.63(1–2), 161–170 (2003).
   PubMed Web of Science ®Google Scholar
• Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J. Consult. Clin. Psychol.47(2), 343–352 (1979).
   PubMed Web of Science ®Google Scholar
• Preston E, Hansen L. A systematic review of suicide rating scales in schizophrenia. Crisis26(4), 170–180 (2005).
   PubMedGoogle Scholar
• Huguelet P, Mohr S, Jung V et al. Effect of religion on suicide attempts in outpatients with schizophrenia or schizo-affective disorders compared with inpatients with non-psychotic disorders. Eur. Psychiatry22(3), 188–194 (2007).
   PubMed Web of Science ®Google Scholar
• Jarbin H, Von Knorring AL. Suicide and suicide attempts in adolescent-onset psychotic disorders. Nord. J. Psychiatry58(2), 115–123 (2004).
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry145(5), 578–583 (1988).
   PubMed Web of Science ®Google Scholar
• Kaplan KJ, Harrow M. Psychosis and functioning as risk factors for later suicidal activity among schizophrenia and schizoaffective patients: a disease-based interactive model. Suicide Life Threat. Behav.29(1), 10–24 (1999).
   PubMed Web of Science ®Google Scholar
• Kaplan KJ, Harrow M, Faull R. Early positive and negative symptoms and poor functioning and later suicidal activity among schizophrenia, schizoaffective and depressive patients. In: Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Science Publishers Inc, NY, USA 49–59 (2007)
   Google Scholar
• Kaplan KJ, Harrow M. Positive and negative symptoms as risk factors for later suicidal activity in schizophrenics versus depressives. Suicide Life Threat. Behav.26(2), 105–121 (1996).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. American Psychiatric Association, TX, USA (2004).
   Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J. Clin. Psychopharmacol.24(5 Suppl. 1), S7–S14 (2004).
   PubMedGoogle Scholar
• Nagamoto HT. Antipsychotic medications. In: Psychiatric Secrets. Jacobson, JL, Jacobson, AM (Eds). Hanley and Belfus Inc., PA, USA 253–259 (2001).
   Google Scholar
• Kane JM. Schizophrenia. N. Engl. J. Med.334(1), 34–41 (1996).
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv.49(2), 196–201 (1998).
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry56(3), 241–247 (1999).
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull.23(4), 637–651 (1997).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60(6), 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol. Drug Saf.12(5), 423–424 (2003).
   PubMed Web of Science ®Google Scholar
• Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin. Ther.28(11), 1912–1921 (2006).
   PubMed Web of Science ®Google Scholar
• Corrigan P. How stigma interferes with mental health care. Am. Psychol.59(7), 614–625 (2004).
   PubMed Web of Science ®Google Scholar
• Carone BJ, Harrow M, Westermeyer JF. Posthospital course and outcome in schizophrenia. Arch. Gen. Psychiatry48(3), 247–253 (1991).
   PubMed Web of Science ®Google Scholar
• Montout C, Casadebaig F, Lagnaoui R et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res.57(2–3), 147–156 (2002).
   PubMed Web of Science ®Google Scholar
• Pompili M, Girardi P, Ruberto A, Tatarelli R. Toward a new prevention of suicide in schizophrenia. World J. Biol. Psychiatry5(4), 201–210 (2004).
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J. Clin. Psychiatry61(Suppl. 3), 4–9 (2000).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. What’s atypical about atypical antipsychotic drugs? Curr.Opin. Pharmacol.4(1), 53–57 (2004).
   PubMed Web of Science ®Google Scholar
• Siris SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am. J. Psychiatry157(9), 1379–1389 (2000).
   PubMed Web of Science ®Google Scholar
• Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum. Psychopharmacol.16(7), 495–505 (2001).
   PubMed Web of Science ®Google Scholar
• Pompili M, Tondo L, Baldessarini RJ. Suicidal risk emerging during antidepressant treatment: recognition and intervention. Clin. Neuropsychiatry2, 66–72 (2005).
   Google Scholar
• Siris SG. Suicide and schizophrenia. J. Psychopharmacol.15(2), 127–135 (2001).
   PubMed Web of Science ®Google Scholar
• Van Putten T, May RP. “Akinetic depression” in schizophrenia. Arch. Gen. Psychiatry35(9), 1101–1107 (1978).
   PubMed Web of Science ®Google Scholar
• Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr. Psychiatry33(4), 221–232 (1992).
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J. Clin. Psychopharmacol.10(1), 12–21 (1990).
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Suicide in schizophrenia. J. Clin. Psychiatry64(9), 1122–1125 (2003).
   PubMed Web of Science ®Google Scholar
• Nordentoftr M, Laursen TM, Agerbo E et al. Change in suicide rates for patients with schizophrenia in Denmark, 1981–97: nested case–control study. Br. Med. J.329(7460), 216– (2004).
   Google Scholar
• Meltzer HY. Decreasing suicide in schizophrenia. Psychiatric Times18, 1–5 (2001).
   Google Scholar
• Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin. Neuropharmacol.18, S18–S24 (1995).
   Google Scholar
• Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk–benefit assessment. Am. J. Psychiatry152(2), 183–190 (1995).
   PubMed Web of Science ®Google Scholar
• Wagstaff A, Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs17(4), 273–280; discussion 281–283 (2003).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. J. Clin. Psychiatry64(9), 1122–1129(2003).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry60(1), 82–91 (2003).
   PubMed Web of Science ®Google Scholar
• Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. J. Clin. Psychiatry66(4), 534–538 (2005).
   PubMed Web of Science ®Google Scholar
• Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res.73(2–3), 139–145 (2005).
   PubMed Web of Science ®Google Scholar
• Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology8(6), 671–677 (1997).
   PubMed Web of Science ®Google Scholar
• Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr. Serv.49(8), 1029–1033 (1998).
   PubMed Web of Science ®Google Scholar
• Munro J, O’Sullivan D, Andrews C et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry175, 576–580 (1999).
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am. J. Psychiatry158(6), 931–937 (2001).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Guzzetta F, Hennen J et al. Effects of psychotropic drug treatments on suicide risk. Presented at:. ACNP 2006 Annual Meeting. Hollywood, FL, USA, 3–7 2006.
   Google Scholar
• Ertugrul A. Clozapine and suicide. Am. J. Psychiatry159(2), 323author reply 324 (2002).
   PubMedGoogle Scholar
• Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr. Psychiatry Rep.4(4), 279–283 (2002).
   PubMedGoogle Scholar
• Meltzer HY. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. J. Clin. Psychiatry66(4), 530–533 (2005).
   PubMed Web of Science ®Google Scholar
• Pompili M, Lester D, Innamorati M et al. Quality of life and suicidal risk in patients with diabetes mellitus. Psychosomatics (In Press).
   Google Scholar
• Turkington D, Kingdon D,Turner T. Effectiveness of a brief cognitive–behavioural therapy intervention in the treatment of schizophrenia. Br. J. Psychiatry180, 523–527 (2002).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Conley RR, De Leo D et al. Intervention strategies for suicidality. J. Clin. Psychiatry6, 1–16 (2003).
   Google Scholar
• Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf.22(1), 73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Beasley CM, Sayler ME, Kiesler GM et al. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia Schizophr.29, 28 (1998).
   Google Scholar
• Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl.)175(2), 215–219 (2004).
   PubMed Web of Science ®Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol.17(5), 407–418 (1997).
   PubMed Web of Science ®Google Scholar
• Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr. Med. Res. Opin.20(9), 1357–1363 (2004).
   PubMed Web of Science ®Google Scholar
• Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry161(10), 1837–1847 (2004).
   PubMed Web of Science ®Google Scholar
• Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress. Anxiety11(2), 80–82 (2000).
   PubMed Web of Science ®Google Scholar
• Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress. Anxiety20, 44–47 (2004).
   PubMed Web of Science ®Google Scholar
• Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J. Psychopharmacol.17(2), 210–215 (2003).
   PubMed Web of Science ®Google Scholar
• Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol. Bull.38(1), 38–45 (2004).
   PubMedGoogle Scholar
• Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs62(8), 1217–1251 (2002).
   PubMed Web of Science ®Google Scholar
• Harvey PD. Ziprasidone and cognition: the evolving story. J. Clin. Psychiatry64(Suppl. 19), 33–39 (2003).
   PubMedGoogle Scholar
• Kivircik Akdede BB, Alptekin K, Kitis A, Arkar H, Akvardar Y. Effects of quetiapine on cognitive functions in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry29(2), 233–238 (2005).
   PubMedGoogle Scholar
• Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs18(13), 877–893 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang PL, Santos JM, Newcomer J et al. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr. Res.71(1), 137–144 (2004).
   PubMedGoogle Scholar
• Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr.9(5), 357–364 (2004).
   PubMed Web of Science ®Google Scholar
• Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr. Clin. North Am.20(2), 427–451 (1997).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Davis P et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord.8(5 Pt 2), 625–639 (2006).
   PubMed Web of Science ®Google Scholar
• Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry68(3), 380–383 (2007).
   PubMed Web of Science ®Google Scholar
• Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. Cochrane Database Syst. Rev.3, CD003834 (2003).
   Google Scholar
• Meltzer HY, Bobo W. Pharmacological management of suicide risk in schizophrenia. In: Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Science Publishers Inc., NY, USA 275–302 (2007).
   Google Scholar
• Baldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. Arch. Gen. Psychiatry63(3), 246–248 (2006).
   PubMedGoogle Scholar
• Plasky P. Antidepressant usage in schizophrenia. Schizophr. Bull.17(4), 649–657 (1991).
   PubMed Web of Science ®Google Scholar
• Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch. Gen. Psychiatry51(2), 109–115 (1994).
   PubMed Web of Science ®Google Scholar
• Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr. Bull.17(1), 75–98 (1991).
   PubMed Web of Science ®Google Scholar
• Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch. Gen. Psychiatry44(6), 533–539 (1987).
   PubMedGoogle Scholar
• Moller HJ. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.254(2), 108–116 (2004).
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr. Res.80(1), 85–97 (2005).
   PubMed Web of Science ®Google Scholar
• Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J. Clin. Psychopharmacol.20(4), 410–416 (2000).
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry162(2), 388–390 (2005).
   PubMed Web of Science ®Google Scholar
• Fohey KD, Hieber R, Nelson LA. The role of selegiline in the treatment of negative symptoms associated with schizophrenia. Ann. Pharmacother.41(5), 851–856 (2007).
   PubMedGoogle Scholar
• Gillies D, Beck A, McCloud A, Rathbone J, Gillies D. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst. Rev.4, CD003079 (2005).
   Google Scholar
• Meyer MC, Baldessarini RJ, Goff DC, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs.Drug Saf.15(5), 333–346 (1996).
   PubMedGoogle Scholar
• Goff DC, Midha KK, Brotman AW et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Psychopharmacol.11(3), 193–197 (1991).
   PubMed Web of Science ®Google Scholar
• Heres S, Davis J, Maino K et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry163(2), 185–194 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery JH, Byerly M, Carmody T et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin. Trials25(6), 598–612 (2004).
   PubMedGoogle Scholar
• Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Can. J. Psychiatry49(9), 601–606 (2004).
   PubMedGoogle Scholar
• Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J. ECT20(1), 13–20 (2004).
   PubMed Web of Science ®Google Scholar
• Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J. ECT21(2), 75–83 (2005).
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost–effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol. Assess.9(9), 1–156, iii–iv (2005).
   PubMed Web of Science ®Google Scholar
• Maltsberger JT, Pompili M, Tatarelli R. Sandro Morselli: schizophrenic solitude, suicide, and psychotherapy. Suicide Life Threat. Behav.36(5), 591–600 (2006).
   PubMedGoogle Scholar
• Hogarty GE, Kornblith SJ, Greenwald D et al. Personal therapy: a disorder-relevant psychotherapy for schizophrenia. Schizophr. Bull.21(3), 379–393 (1995).
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Greenwald D, Ulrich RF et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. Am. J. Psychiatry154(11), 1514–1524 (1997).
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Kornblith SJ, Greenwald D et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Am. J. Psychiatry154(11), 1504–1513 (1997).
   PubMed Web of Science ®Google Scholar
• De Leo D, Spathonis K. Do psychosocial and pharmacological interventions reduce suicide in schizophrenia and schizophrenia spectrum disorders? Arch. Suicide Res.7(4), 353–374 (2003).
   Google Scholar
• Motto JA, Bostrom AG. A randomized controlled trial of postcrisis suicide prevention. Psychiatr. Serv.52(6), 828–833 (2001).
   PubMed Web of Science ®Google Scholar
• Tarrier N, Haddock G, Lewis S, Drake R, Gregg L. Suicide behaviour over 18 months in recent onset schizophrenic patients: the effects of CBT. Schizophr. Res.83(1), 15–27 (2006).
   PubMed Web of Science ®Google Scholar
• Tarrier N, Gooding P, Gregg L, Johnson J, Drake R. Suicide schema in schizophrenia: the effect of emotional reactivity, negative symptoms and schema elaboration. Behav. Res. Ther.2090–2097 (2007).
   PubMedGoogle Scholar
• Bateman K, Hansen L, Turkington D, Kingdon D. Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. Suicide Life Threat. Behav.37(3), 284–290 (2007).
   PubMed Web of Science ®Google Scholar
• Tacchi MJ, Scott J. Improving Adherence in Schizophrenia and Bipolar Disorders. Wiley, Chichester, UK (2005).
   Google Scholar
• Davis JM, Kane JM, Marder SR et al. Dose response of prophylactic antipsychotics. J. Clin. Psychiatry54(Suppl.), 24–30 (1993).
   PubMed Web of Science ®Google Scholar
• Valenstein M, Blow FC, Copeland LA et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull.30(2), 255–264 (2004).
   PubMed Web of Science ®Google Scholar
• Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv.54(5), 719–723 (2003).
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry161(4), 692–699 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas P. The stable patient with schizophrenia – from antipsychotic effectiveness to adherence. Eur. Neuropsychopharmacol.17(Suppl. 2), S115–S122 (2007).
   Web of Science ®Google Scholar
• Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J. Clin. Psychiatry59(Suppl. 3), 31–37 (1998).
   PubMed Web of Science ®Google Scholar
• Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J. Clin. Psychiatry68(Suppl. 4), 14–18 (2007).
   PubMedGoogle Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J. Clin. Psychiatry68(Suppl. 4), 34–39 (2007).
   PubMedGoogle Scholar
• Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J. Clin. Psychiatry68(Suppl. 4), 19–25 (2007).
   PubMed Web of Science ®Google Scholar
• Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J. Clin. Psychiatry68(Suppl. 4), 26–33 (2007).
   PubMed Web of Science ®Google Scholar
• Goff DC. Integrating general health care in private community psychiatry practice. J. Clin. Psychiatry68(Suppl. 4), 49–54 (2007).
   PubMedGoogle Scholar
• Parks JJ. Implementing practice guidelines: lessons from public mental health settings. J. Clin. Psychiatry68(Suppl. 4), 45–48 (2007).
   PubMed Web of Science ®Google Scholar
• Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J. Clin. Psychiatry68(Suppl. 4), 40–44 (2007).
   PubMed Web of Science ®Google Scholar
• Hudson TJ, Owen RR, Thrush CR et al. A pilot study of barriers to medication adherence in schizophrenia. J. Clin. Psychiatry65(2), 211–216 (2004).
   PubMed Web of Science ®Google Scholar
• Pompili M, Mancinelli I, Girardi P, Tatarelli R. Preventing suicide in schizophrenia inside the family environment. Crisis24(4), 181–182 (2003).
   PubMedGoogle Scholar
• Pompili M, Girardi P, Ruberto A, Kotzalidis GD, Tatarelli R. Emergency staff reactions to suicidal and self-harming patients. Eur. J. Emerg. Med.12(4), 169–178 (2005).
   PubMed Web of Science ®Google Scholar
• Pompili M, Mancinelli I, Tatarelli R. Stigma as a cause of suicide. Br. J. Psychiatry183, 173–174 (2003).
   PubMed Web of Science ®Google Scholar
• Pompili M, Tatarelli C, Kotzalidis GD, Tatarelli R. Suicide risk in substance abusers with schizophrenia. In:Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Publishers Inc., NY, USA157–174 (2007).
   Google Scholar
• Montross LP, Zissok S, Kasckow J. Command hallucinations and suicide risk. In: Suicide in Schizophrenia. Tatarelli R, Pompili M, Girardi P (Eds). Nova Science Publishers Inc., NY, USA 113–132 (2007).
   Google Scholar
• Harkavy-Friedman JM, Kimhy D, Nelson EA et al. Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. J. Clin. Psychiatry64(8), 871–874 (2003).
   PubMed Web of Science ®Google Scholar
• Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann. NY Acad. Sci.932, 94–102; discussion 102–105 (2001).
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Pompili M, Tondo L. Bipolar disorder. In: American Psychiatric Textbook of Suicide Assessment and Management. Simon, RI, Hales, RE (Eds). American Psychiatric Publishing, Washington, DC, USA 277–299 (2006).
   Google Scholar
• Phelan JC, Bromet EJ, Link BG. Psychiatric illness and family stigma. Schizophr. Bull.24(1), 115–126 (1998).
   PubMed Web of Science ®Google Scholar
• Corrigan PW, Phelan SM. Social support and recovery in people with serious mental illnesses. Community Ment. Health J.40(6), 513–523 (2004).
   PubMed Web of Science ®Google Scholar
• Pompili M, Mancinelli I, Girardi P, Tatarelli R. Nursing schizophrenic patients who are at risk of suicide. J. Psychiatr. Ment. Health Nurs.10, 622–624 (2003).
   PubMedGoogle Scholar
• Pompili M, Mancinelli I, Girardi P, Tatarelli R. Making sense of nurses’ role in the prevention of suicide in schizophrenia. Issues Ment. Health Nurs.25, 5–7 (2004).
   PubMedGoogle Scholar